Vraylar

Product manufactured by Allergan, Inc.

Application Nr Approved Date Route Status External Links
NDA204370 None Oral None Google , Wikipedia , PubMed , DailyMed , Raw OpenFDA , ECHA , ToxNet , JECFA , FAO , 21 CFR

Indications and Purposes

1. Indications And Usage Vraylar® Is Indicated For The: • Treatment Of Schizophrenia In Adults [See Clinical Studies ( 14.1 )] • Acute Treatment Of Manic Or Mixed Episodes Associated With Bipolar I Disorder In Adults [See Clinical Studies ( 14.2 )] • Treatment Of Depressive Episodes Associated With Bipolar I Disorder (Bipolar Depression) In Adults [See Clinical Studies ( 14.3 )] Vraylar Is An Atypical Antipsychotic Indicated For The: Treatment Of Schizophrenia In Adults ( 1 ) Acute Treatment Of Manic Or Mixed Episodes Associated With Bipolar I Disorder In Adults ( 1 ) Treatment Of Depressive Episodes Associated With Bipolar I Disorder (Bipolar Depression) In Adults ( 1 )

All Formulated Excipients (0 Total)

None

Active Ingredients ( 1 Total)

Name Structure ZINC ID(s)
1. Cariprazine CARIPRAZINE ZINC100153731

Comments